The sales are too small relative to market cap to warrant a bearish stance. Monitor for any unplanned insider sales in the next 30 days; if a pattern of C-suite selling continues above 0.5% of market cap, that would be a more credible signal. For now, the cluster reads as routine diversification.
IMNM drugs
IMNM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 10 $23.35entry
- T+1 · 4mo ago −2.36%α −1.59% · $22.80
- T+5 · 4mo ago −4.93%α −4.36% · $22.20
- T+20 · 3mo ago +7.19%α +4.77% · $25.03
- T+60 · 6w ago −9.34%α −11.97% · $21.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Immunome insiders sold a total of ~$813K in open-market shares over a one-week window ending July 7, 2026, including the Chief Business Officer, the Chief Medical Officer, and a Director. Director Barchas Isaac alone sold ~$2.4M across two days (July 6–7), making this the dominant insider transaction. At ~0.03% of Immunome's $2.7B market cap, the total sales are trivial in proportional terms, and cluster sales are weak directional signals per the academic literature. The sales are best interpreted as routine portfolio diversification, not a bearish corporate signal.
Key Financial Metrics
Key Facts
- Three insiders sold shares: Director Isaac Barchas ($2.4M), CBO Horn Kinney ($27K + option exercise), CMO Robert Lechleider ($377K)
- Total open-market sales: ~$2.84M; total cluster value after netting derivative exercises: ~$813K
- Sales represent ~0.1% of Immunome's $2.7B market cap
- No insider purchases were filed in this cluster window
Financial Impact
$2.84M in total insider open-market sales, or ~0.1% of market cap
Risk Factors
- Additional insider selling in coming weeks could signal deteriorating conviction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IMNM-1783634473409 |
Track record
20 reports on IMNM
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers